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ABSTRACT
Background The Department of Health introduced a risk assessment, management and reduction programme, NHS Health Checks, which aimed
to reduce premature morbidity and mortality from cardiovascular diseases for those aged 40–74. Those identified as at increased risk of CVD are
offered prophylactic medication and lifestyle advice to reduce their risk. Health gains will only be achieved if patients are compliant with advice/
intervention however. This study sought to understand factors that influenced adherence to medication and advice in ‘high-risk’ patients.
Methods Qualitative data were collected through 29 semi-structured interviews with a purposive sample of individuals who had been identified
as at high-risk of CVD. Participants had been offered lifestyle advice, lipid lowering medications and attended at least one annual review.
Results Findings explore the challenges and experiences confronting ‘high-risk’ individuals when making decisions about engaging with
intervention. Key findings explore: statin adherence, as well as adherence to advice about diet, physical activity, alcohol consumption and smoking
cessation.
Conclusions Attention needs to be paid to the way prophylactic medications are prescribed and explained to high-risk patients. Consistent
provision of tailored lifestyle advice and access to appropriate services could facilitate sustained changes to factors that increase CVD risk.
Keywords public health, screening, health services
Background
It is widely believed that the majority of deaths that are attrib-
uted to cardiovascular diseases (CVD) could be prevented
through the early identification of risk factors (for example,
underlying physiological conditions such as hypertension,
dyslipidaemia, diabetes and chronic kidney disease) and
through the facilitation of lifestyle changes.1–3 It is said that
identification of these risk factors and promotion of lifestyle
changes to diet, physical activity, smoking and alcohol con-
sumption could achieve a large reduction in mortality and
morbidity associated with CVD1,4 and reduce the economic
burden experienced by the National Health Service (NHS).5–7
However, the focus on so-called lifestyle factors tends to per-
sonalize the issues and frame them in terms solely of individual
responsibility, deflecting attention from the social determinants
of health. We know that in England, the burden of CVD is
felt disproportionately in disadvantaged communities and
therefore owes much to structural conditions of class and
poverty.8 Mortality attributed to CVD has been falling for the
population as a whole by 6% per year; however, this reduc-
tion has been experienced differently between socioeconomic
groups, meaning that whilst overall rates fall, health inequal-
ities are increasing.9 A major challenge for NHS Health
Check (NHSHC) is therefore to reduce death and illness from
CVD overall without actually increasing inequalities.
In the UK, the Department of Health (DH) has responded
to this situation by developing a national CVD risk
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assessment, management and reduction programme: the
NHSHC4,10 which was launched in 2009. The NHSHC
aimed to offer CVD risk assessment to the entire population
of 40–74 year olds in England and Wales within the first 5
years of the programme’s implementation (by 2013).4,10
However, this aspirational target has yet to be achieved.
Individuals who do not have pre-existing CVD or diabetes
are invited to attend an appointment with their primary care
practitioner to undergo an assessment of their risk of suffer-
ing a cardiovascular event in the next 10 years. This assess-
ment includes the collection of anthropometric
measurements, noting of family medical history and choles-
terol testing. A calculation is then performed to assess the
individual’s CVD risk, and the outcome expressed as a per-
centage chance of suffering an adverse event in the next 10
years. Those individuals identified as being at 20% risk or
higher are classed as ‘high risk’ and are therefore eligible for
lifestyle advice and intervention with prophylactic medication
(commonly statins) to reduce and manage their CVD risk.10
Initially, the commissioning of the NHSHC at the local
level was the responsibility of Primary Care Trusts (PCTs).
However, with the 2013 restructuring of the NHS, this
responsibility was passed to Local Government11,12 with
support from Public Health England.13 PCTs were originally
given scope to develop the NHSHC programme in a way that
suited the needs of their local population, whilst being
mindful of the need to provide equity of access and avoid
increasing health inequalities.10
In the study area NHSHCs were offered primarily through
general practitioner (GP) surgeries, but also through commu-
nity pharmacies14 (subsequently decommissioned) and in
workplaces and other community settings, in an attempt to
provide equity of access for the local population.
Under the current (national and local) guidance,4 once an
individual has received an NHSHC and has been identified as
at high risk of CVD (.20%) they are offered lifestyle advice,
and in many cases will also be offered a lipid lowering medica-
tion (statin) for the purposes of prevention. In order to be
successful the NHSHC must not only identify those at risk
and offer intervention, it must also engage—and then sustain
engagement—of the individual to comply with the interven-
tion. Individuals must not only accept their invitation for as-
sessment but also understand why they have been identified
as at risk, understand advice given to them and adhere to any
interventions offered over the long term. Without this adher-
ence to the programme, the putative gains to the NHS from
preventive15 action are unlikely to be realized.
This study reports on findings from a qualitative study that
sought to understand patients’ experiences of, and compliance
with, forms of intervention offered as part of the NHSHC.
Methods
Data described in this study were collected through 29 semi-
structured interviews with patients who had received an
NHSHC between 2009 and 2012. Participants were recruited
through five GP practices located across four PCT areas in
the North East of England, after they had attended an annual
review. Those patients who agreed in principle to take part
were provided with written information about the project to
facilitate informed consent.
All participants had received an NHSHC, had been identi-
fied as at high risk (.20% of having an adverse cardiovascu-
lar event in the next 10 years), had received lifestyle advice
and/or been prescribed a statin and had attended at least one
annual review. These participants were chosen due to their ex-
perience of the NHSHC programme and because they had
already had the opportunity to initiate and sustain lifestyle
changes/medication regimens over a period of at least 1 year.
Interviews were normally conducted in the participant’s own
home on a one-to-one basis, with the exception of three inter-
views where the participant’s spouse was also present.
Interviews were conducted using a semi-structured inter-
view schedule to facilitate frank and open discussions about
the NHSHC and engagement with lifestyle advice and medical
intervention. The interview schedule was developed using
Normalisation Process Theory16–19 as a framework to sensi-
tize the researchers to the process of implementing, embed-
ding and integrating new practices into everyday life.
Interviews were, with the permission of the participants,
recorded and transcribed verbatim. Data were anonymized
and subjected to a six-stage thematic analysis.20 Initially, the
researchers undertook a familiarization stage of analysis
which led to the identification of initial codes. These codes
were then applied to the whole dataset to enable the collation
of codes into preliminary themes. These themes were
reviewed by both researchers to produce a revised set of
themes that were named and finalized. In the final stage quo-
tations were selected which illustrated the thematic framework
that had been generated. NVivo 9 was used to facilitate data
management during the analysis stage.
The project proposal was scrutinized and approved by
Teesside University School of Health and Social Care
Research Ethics and Governance Committee.
Results
Responses presented in this study are from 19 males and 10
females who were aged between 53 and 76 years old at the
time of interview (see Table 1). During interviews participants
were asked to recall if they had been offered lifestyle advice
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and access to services and if they had made changes to their
lifestyle based on the advice received. Participants were also
asked to recall if they had been offered a statin as a result of
their risk assessment and, if they had, then initiated and con-
tinued treatment. An overview of the number of responses
about each topic can be found in Table 2.
Statin adherence
All participants were asymptomatic before attending their
Health Check; they had been invited for assessment, not
sought it out. The majority (n ¼ 27) were offered a statin for
the purposes of prevention; only two participants had not
been offered a statin as a result of their assessment.
Of the 27 participants who had been offered a statin, four
had refused outright. However, 23 had initiated statin treat-
ment. During the course of the first year, 5 of the 23 had dis-
continued taking the statin permanently.
Whilst 18 participants had continued to take a statin for at
least 1 year, post-risk assessment, this sustained compliance
was due, in part, to a number of individuals being afforded
the opportunity to reconfigure their medications. Side effects
that were attributed to statin treatment were the main reason
for wanting to discontinue the initially prescribed treatment.
Many participants recounted the side effects they had experi-
enced, which ranged in severity from mild, tolerable side
effects (e.g. gastric discomfort) to symptoms that were really
quite debilitating in some cases (e.g. severe muscular pains
and heaviness of limbs). Upon experiencing side effects
which participants attributed to the commencement of statin
treatment, a number of them approached their GP or practice
nurse to discuss the side effects. The majority of these partici-
pants were offered the opportunity to swap from the brand of
statin they were currently taking to a new brand, in the hope
that they would tolerate the medication better. In all of these
cases participants noted that the side effects had disappeared
and that they were happy to continue taking the new brand of
medication as long as they were able to tolerate it. The oppor-
tunity to reconfigure medications was not the same in all GP
practices. When some participants had returned to their prac-
tice to discuss the side effects they were experiencing, they
had been turned away and told that their current brand was
the only one that could be offered—in these cases all of the
participants discontinued using statin. It was also reported
that participants had discontinued statin treatment without
returning to their practice due to the side effects they had
suffered.
Testing for high cholesterol and trying to treat it through
making dietary changes or by taking statin medication is a fa-
miliar concept in the UK, and it is often discussed in the na-
tional press and media. The topic of cholesterol management
was often discussed in interview and many participants high-
lighted that they had been advised to take a drug that they
understood was being promoted for cholesterol reduction for
a new purpose—prevention, rather than cure. Statins were, in
the eyes of participants, now being offered regardless of
cholesterol levels or whether an individual’s cholesterol was
inside or outside the current recommended thresholds. This
Table 2 Breakdown of sample by medication status and adherence to lifestyle change
n ¼ 29 Not discussed at health check Discussed: no changes made Discontinued treatment Successful change
Statin medication 2 4 (statin refused at HC) 5 18
Dietary change 4 9 — 16
Increased physical activity 19 8 — 2
Reduced alcohol consumption 24 4 — 1
Smoking cessation 10 (non-smokers)
15 (ex-smokers)
3 — 1 (quit)
Table 1 Demographic characteristics of sample (sex, age, IMD quintile)
Sex Male Female
No. participants 19 10
Age in years 51–55 56–60 61–65 66–70 71–74 75þ
No. participants 1 4 7 9 7 1
IMD (2010) quintile Quintile 1 (least deprived) Quintile 2 Quintile 3 Quintile 4 Quintile 5 (most deprived)
No. participants 13 7 5 3 1
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apparent lack of regard for prescription according to mea-
sured cholesterol levels caused confusion and anxiety. New
concepts such as high-density lipoprotein level (HDL/‘good
cholesterol’) and low-density lipoprotein level (LDL/‘bad
cholesterol’) were being introduced into discussion in consul-
tations as a way of encouraging people to commence statin
treatment. However, this only served to muddy people’s
understanding of concepts they had previously thought they
had a grasp on (Box 1).
Box 1 Statin adherence
They’re fine. I mean I take it before I go to bed at night but,
[laughs] it’s when you get to bed. . .it bubbles in here [pats
tummy]. . . I get wind, terrible wind, just bubbling away in here.
Seemingly that’s a side effect of them (P11, Female, taking
statin).
Well they [legs] stiffened up. It felt as though you’d been
stood in a bucket of concrete! And, I got diarrhoea and felt sick
and had a fuzzy head with them. They said [GP staff] ‘well you
usually get this over the first three months’. It didn’t ease off
and I thought [to myself ] ‘well, I felt perfectly well before I went
on these; I’d like to come off them’ (P13, Male, taking statin).
I went in [to the GP practice] and got them [statin] and she
gave me a supply. I started taking them and all [of the] muscles
in my back started jumping around like that [gestures with
hands]. [I thought] ‘I can’t go on like this’ and so I rang up [GP
practice] and said ‘I’m not taking them’ (P19, Male, discontin-
ued statin).
Interviewer: So if you had some sort of ‘event’ like a heart
attack or a stroke, you would be happy to take them [statin]?
Respondent: Yes, because then it could be lifesaving! But I’m
not too sure about [taking them] just for prevention? I mean
there’s no way that I would go and have a double breast oper-
ation, removal, just because I am at high risk of breast cancer—I
just wouldn’t do it (P5, Female, refused statin).
I was aware of my cholesterol, and have been for over 15
years. . .[it is always] about 3.5. That’s about what my choles-
terol is, you know, always has been. She [the nurse] said ‘yeah,
but your bad cholesterol is higher than your good cholesterol’.
I thought ‘what’s she on?’ ‘Where’s she coming from?’ ‘Bad’
cholesterol, ‘good’ cholesterol. . .never heard of it! (P15, Male,
taking statin).
Advice about diet
Recollection of dietary advice in the NHSHC consultation was
high. Twenty-five participants recalled being offered advice
about their diet; 16 participants stated that they had made some
changes to their eating habits based on that advice; 9 partici-
pants stated that they had made no changes to their eating
habits; 4 participants could not recall being offered any advice.
Participants were happy to discuss diet as part of their
NHSHC, but how these discussions were broached had an
impact on the participant’s experience, especially when these
discussions were framed in the context of losing weight.
Identification of individuals as obese had the potential to
leave them with negative feelings about the whole assessment.
For many participants, making small and sustainable
changes to their diet by consuming less salt and fat was
achievable, as long as it did not cause too much disruption to
their daily routines. A number of older participants felt that
making changes to their lifestyle was unnecessary at their age,
and the provision of healthy eating information was not
always accepted and was branded too generic. There was a call
for dietary advice that was CVD risk reduction focussed, as
opposed to the normal information that could be picked up
from any doctor’s waiting room.
Like the discussions about thresholds for cholesterol and
how they seemed to alter frequently, people showed reluctance
to make changes to their lifestyle, noting that any guidance they
were given was likely to be subject to change. Many cited the
consumption of eggs as an example, stating that previous guid-
ance about healthy eating suggested that the consumption of
eggs should be restricted; then the reverse was promoted—eggs
were recommended as part of a healthy balanced diet (Box 2).
Box 2 Advice about diet
I must admit, when she [the nurse] said to me that I was ‘obese’
I was devastated. . .it really shocked me, didn’t it? [husband
nods]. I couldn’t get over it. I was really like ‘I can’t believe I’m
obese’ (P3, Female, discontinued statin).
You know, I’m 72 this year and you think to yourself ‘oh
crumbs, I’m done!’ I am eating everything right. We both [he
and his wife] have a drink, we like a drink, but if my main
doctor says ‘just go and live your life, that’s what I do (P19,
Male, discontinued statin).
She [ the nurse] gave me some paraphernalia [about healthy
eating] but it was a waste of money giving me that, because I
just didn’t bother with it. . .I’m quite happy [the way I am] (P17,
Male, taking statin).
They say eat margarine, then butter is better for you, [then]
don’t eat margarine. That’s what I’m saying, I don’t take any
notice of all of these ‘you must eat this’ because two years later
they are saying they are good for you. . .at one time eggs was
bad for you, do you remember? Then they decided, no, eggs
are good for you (P27, Male, discontinued statin).
Advice about physical activity
When asked to recall advice that had been offered with regard
to physical activity levels, 10 participants recalled receiving
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advice and 2 went on to take action and increase their person-
al physical activity levels. Eight participants did not make any
changes to physical activity levels based on the advice they
were given; 19 participants could not recall being offered any
advice about physical activity levels. No one recalled being
offered a referral to physical activity programmes either ‘in
house’ at the GP practice or in a community setting.
Many interviewees were already fairly active before they
attended their NHSHC. Many enjoyed swimming, walking
and group activities such as bowls on a regular basis.
However, many found that due to their advancing age, they
were restricted in what activities they could now undertake.
These people preferred to incorporate physical activity into
their daily lives, through activities such as gardening, which in
itself was often challenging, especially when they had co-
morbidities such as arthritis, and they were of the view that
any physical activity intervention suggested to them would
have to take these impairments into account if it were to be
acceptable (Box 3).
Box 3 Advice about physical activity
On average, I walk four miles a day. I go on the hills [and] climb
(P27, Male, discontinued statin).
I mean I bowl twice a week; green bowling, lawn bowling,
and in the wintertime it’s once a week because we do carpet
bowls and I walk up and down the village every day (P11,
Female, taking statin).
I don’t feel old, but then my body is telling me that I am. I
tried running, because I used to be cross country at school. But
now I can’t run 5 yards, and it’s my body telling me that I’m old.
I only feel 19 but then when I try to do something, I know I’m
not (P8, Male, taking statin).
I can garden and that, but I have got arthritis and so I battle a
bit. I have got a thing that I kneel on to get up and down (P28,
Female, taking statin).
Advice about alcohol consumption
Discussions about alcohol consumption were recalled less fre-
quently. When asked to recall if they had been offered advice
about alcohol consumption, five participants could recall
being offered advice. One participant made changes to his/
her alcohol consumption based on that advice, whilst 24 par-
ticipants could not recall being offered any advice about
alcohol consumption.
For the majority of participants, alcohol consumption was
not discussed but they felt that their alcohol consumption was
within guideline amounts, and for those who had discussed
their consumption with the nurse at the HHC, this had been
reiterated during discussions. There was only a small minority
who had decided to reject advice from the nurse (Box 4).
Box 4 Advice about alcohol consumption
She said I was quite in the limit of what I drank. You know,
because we have wine on a Sunday and a couple of brandies
sometimes. Not two on a night, but one on a night, a couple of
times a week (P11, Female, taking statin).
[the nurse said] ‘I think you should have two nights off.
‘Oooooh’ I said ‘which nights would they be [nurse’s name]?
[The nurse said] ‘Monday and Sunday?’ [I said] ‘No, after line
dancing it’s my cricket club night!’ (P9, Female, refused statin).
Advice about smoking cessation
The majority of participants were either non-smokers (n ¼
10) or ex-smokers (n ¼ 15) so had not been offered smoking
cessation advice. Four participants were smokers at the time
of their risk assessment and were offered smoking cessation.
One of these smokers went on to quit smoking as a result of
the smoking cessation offered during the risk assessment.
Amongst those who had discussed smoking cessation and
declined the invitation, there was a feeling that it was being
offered to them too late in their lives to make any difference
to their health (Box 5).
Box 5 Advice about smoking cessation
. . .it’s too late, yeah? It’s far too late. I mean 67, say I live
another 20 year, [that would make me] 87, which would be bril-
liant but it would take 20 year minimum for my lungs to clear,
minimum (P15, Male, taking statin).
Discussion
Main findings of this study
All participants had engaged with the NHSHC programme
insofar as they had attended their assessment, been offered
advice and gone on to attend at least one annual review—
making them already somewhat compliant with the pro-
gramme. Nevertheless, the advice they were offered at the
time of assessment and subsequent initiation and adherence
to lifestyle changes and lipid lowering medications was highly
variable within the sample.
Discussions about lifestyle changes were broached variably,
with discussion about diet happening most frequently.
Discussion about physical activity and alcohol consumption
happened much less frequently and indicates an area for im-
provement within the programme. People were more
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receptive to making small but manageable changes to their
lifestyle and they were open to the provision of information
about how to reduce CVD risk through dietary changes.
However, they were confused (and somewhat undermined)
by the fact that guidance could be subject to change. When it
came to the promotion of increased physical activity, people
highlighted that there would need to be consideration of
those who experienced co-morbidities often associated with
ageing.
Side effects from statin were the main reason for discon-
tinuation of drug treatment. How discussions about side
effects were handled by health professionals had a great
bearing on a participant’s decision to try a different brand or
to discontinue treatment on a permanent basis. Participants
did not distinguish between the effect of statin to lower chol-
esterol or its promoted overall preventative effects.
The promised benefits from this universal intervention are
theoretical rather than proven at this stage in the production
of empirical evidence. Predicted gains from modelling
assume high levels of compliance after testing and identifica-
tion of ‘high-risk’ patients. This qualitative study indicates first
a level of variability amongst health-care professionals in
raising for discussion, post-test, different aspects of the avail-
able drug and lifestyle treatments. Secondly, it indicates that
patients experiencing side effects from statins are more likely
to remain adherent if GPs are willing to listen to their con-
cerns and review medication. Thirdly, the study emphasizes
that for patients deemed to be at high risk the Health Check
is not so much an event as the start of a process of adaptation
to a new lifestyle which requires far more personalized and
tailored advice on diet and activity suitable for people in later
age and possibly with existing co-morbidities.
What is already known on this topic?
The DH’s modelling exercise estimated that, if successfully
implemented, the NHSHC could be cost-effective.15 However,
early real-world findings suggest that uptake is lower than
expected21,22 and that national coverage stands at 8%, well below
the DH’s expected coverage of 18% by 2012.23 In 2012
NHSHCs came under criticism as the intervention had been
rolled out based upon theoretical modelling and not on evidence
from randomized controlled trials,24 leading to calls for the
abandonment of the NHSHC programme until the evidence
base for effectiveness is stronger.25 Rebuttals have been played
out in the BMJ, defending the universal programme,26 but
with some authors advocating the development of a targeted
programme,27,28 rather than the current universal approach.
Socioeconomic status, ethnicity and gender have all been
positively associated with increased risk of CVD and it is
known that many interventions can actually increase health in-
equalities.9,29 It has been suggested that, rather than taking a
universal approach to identifying and treating risk factors
(which may increase inequalities even more as a consequence
of differential uptake), a population approach (focusing on
deprivation and population wide policies, e.g. tobacco control
or making healthy food choices affordable) to promote car-
diovascular health would be both more effective and more
cost-effective.30–34
Although statins have been found to be effective in the
primary prevention of CVD,35 previous studies have found that
overall adherence to treatment is low, with only half of those
prescribed statin taking them on a daily basis.36 Patients receiv-
ing treatment with statin for primary prevention, as opposed to
secondary prevention, are more likely to discontinue treat-
ment.37,38 Side effects are often cited as the reason for discon-
tinuation of statin treatment,39 as was found in our study.
What this study adds
Much of the published work on NHSHCs so far has focussed
on implementation, uptake and coverage of the UK pro-
gramme. The focus in these studies has been on initial assess-
ments and conversion of invitations into assessments for
example. Less attention has been paid to the longer term ad-
herence amongst those individuals who have been identified
as at high risk of CVD. It is important, especially in a time of
depleted budgets, to ensure that any intervention is offered to
the right people, at the right time and most importantly that
those people are accepting of and compliant with the inter-
vention. If this does not happen, the NHSHC programme
cannot realize its full potential.
This study suggests that attention needs to be paid to a
more sophisticated prescription of prophylactic medications
to reduce CVD risk and also to better explanation of their
virtues and value to patients. The study also suggests the need
for provision of more tailored lifestyle advice and access to
appropriate services to facilitate sustained changes to factors
that could increase CVD risk.
Limitations of this study
Findings in this study are derived from a relatively small
number of interviews with individuals identified as at high
risk. All were White British (reflecting the demographic
balance in the catchment studied however) and the majority
were residents in the least deprived quintiles of Tees (Table 2).
With qualitative studies generalizability achieved through
having a large, representative sample, is not the aim. Rather,
we seek insights developed through looking at issues in great
depth, but further studies of compliance in patients from
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more deprived quintiles or from populations with different
ethnicity are clearly called for.
Participants were asked to recall what lifestyle advice and
medical intervention had been offered to them some time
ago. The lapse of at least 1 year (patients were contacted after
their first annual review) may have affected the accuracy of
their recall around what was offered in terms of lifestyle
advice/intervention, but their current behaviour is clearly
determined by their memory and understanding of that
encounter.
Findings were drawn from interviews with people who
were already compliant with some aspects of the NHSHC
programme. We have no data from people who:
(1) failed to attend their risk assessment (refusers) or
(2) attended their risk assessment but did not attend an
annual review (dropouts).
Further qualitative research is needed to understand the needs
and experiences of these two groups and should include re-
presentation from ethnically diverse populations.
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